Inmarsat Plc

Inmarsat takeover to be probed for national security and competition issues

The Competition & Markets Authority will extend its investigation to include any concerns over national security or competition

Inmarsat has agreed to be taken over by a consortium of UK and US private equity groups and Canadian pension funds

The takeover of satellite operator Inmarsat Plc (LON:ISAT) by a private equity-led consortium is to be investigated in the interests of national security.

Culture secretary Jeremy Wright said late on Monday that a review of the US$3.4bn take-private deal will be extended to include national security after his department received representations from the secretary of state for defence, the business secretary and the foreign secretary.

READ: CMA launches probe into Inmarsat takeover for potential competition issues

Last week, the Competition & Markets Authority brought the deal to the attention of the Secretary of State for Digital, Culture, Media & Sport as it may reduce competition in the market.

On Tuesday the CMA extended its invitation to interested parties to comment on not only the impact of the transaction on competition but also any public interest considerations, with responses due by 5 August.

Inmarsat in March agreed to be bought by a four-way consortium made up of private equity firms Apax Partners and Warburg Pincus, plus two Canadian pension plan boards.

On Monday, the UK Secretary of State for Culture, Media, & Sport, who has the power to intervene on national security grounds, issued a public interest intervention order.

New UK rules were introduced last year applying to takeovers by foreign companies, after concerns were raised that sensitive technology was being snaffed by foreign buyers.

The CMA will report to the government by 17 September, including any concerns over both national security or competition.

Inmarsat shares were down 1.4% to 554.6p on Tuesday morning.

Quick facts: Inmarsat Plc

Price: £5.78

Market: LSE
Market Cap: £2.68 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

3 hours, 21 minutes ago


Holding(s) in Company

9 hours, 54 minutes ago

Form 8.3 - Inmarsat plc

12 hours, 53 minutes ago

Form 8.3 - Inmarsat plc

12 hours, 55 minutes ago

Form 8.3 - Inmarsat

13 hours, 15 minutes ago

Form 8.3 - Inmarsat PLC

13 hours, 24 minutes ago

Form 8.3 - Inmarsat PLC

14 hours, 25 minutes ago

2 min read